subscribeSubscribe
Novartis faces one win, one loss in patent cases over heart failure drug

Novartis faces one win, one loss in patent cases over heart failure drug
Paul Schloesser ENDPTS
11 Jul 2023
Share Share
Novartis will appeal to U.S. Court of Appeals to uphold validity of Entresto combination patent

Novartis will appeal to U.S. Court of Appeals to uphold validity of Entresto combination patent
PRESS RELEASE
07 Jul 2023
Share Share
Novartis Entresto receives positive CHMP opinion for pediatric heart failure

Novartis Entresto receives positive CHMP opinion for pediatric heart failure
PRESS RELEASE
01 Apr 2023
Share Share
We are pleased to inform you that Sacubitril Valsartan`s USDMF has been successfully submitted to the USFDA. Our process experts developed Sacubitril Valsartan

We are pleased to inform you that Sacubitril Valsartan`s USDMF has been successfully submitted to the USFDA. Our process experts developed Sacubitril Valsartan
PRESS RELEASE
09 Mar 2023
Share Share
HC reserves order on Natco`s plea over patent for Novartis drug

HC reserves order on Natco`s plea over patent for Novartis drug
ECONOMIC TIMES
11 Jan 2023
Share Share
JB Pharma cuts price of its top-selling heart failure drug Azmarda by 50%

JB Pharma cuts price of its top-selling heart failure drug Azmarda by 50%
Viswanath Pilla ECONOMICTIMES
06 Dec 2022
Share Share
Novartis files another Entresto patent suit to fight generics

Novartis files another Entresto patent suit to fight generics
Zoey Becker FIERCEPHARMA
27 Oct 2022
Share Share
Novartis hit with Entresto patent suit amid generics fight

Novartis hit with Entresto patent suit amid generics fight
Angus Liu FIERCEPHARMA
31 Aug 2022
Share Share
Novartis income edges higher on strong Sandoz, Entresto

Novartis income edges higher on strong Sandoz, Entresto
Ludwig Burger REUTERS
27 Apr 2022
Share Share
Novartis petitions FDA to block 18 generic competitors for its megablockbuster

Novartis petitions FDA to block 18 generic competitors for its megablockbuster
Zachary Brennan ENDPTS
07 Dec 2021
Share Share